A new recombinant H5N1 vaccine virus has been
developed in China and is available for researchers and companies that want to
develop or produce the H5N1 vaccine for human use, an official with the Chinese
Center for Disease Control and Prevention (CDC) said.
Shu Yuelong, senior official with Chinese CDC, said the new vaccine virus was
developed by the Chinese CDC and U.S. CDC from the cases of human infections of
the deadly virus in southern China.
Researchers found that a newly isolated virus collected from people infected
with H5N1 in southern China was distinguishable in terms of antigen from the
viruses that had previously been selected for vaccine development, Shu said.
Shu said it was the first time for China to develop a new humanH5N1 vaccine
virus, which will be a great contribution to the prevention of the fatal
The World Health Organization (WHO) has put the new development on its Web
site and said it's available for "institutions, companies and others interested
in pandemic vaccine development."
The cases of human infection with bird flu in China numbered 13in 2006, and
seven in 2005.
In August 2006, the WHO found that there was antigenic variation among the
recent H5N1 viruses. Since then, the WHO Collaborating Centers and H5 Reference
Laboratories have been developing several new recombinant H5N1 vaccine